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Abstract
Background: We consider the problem of optimizing a liposomal drug formulation: a complex chemical system with many
components (e.g., elements of a lipid library) that interact nonlinearly and synergistically in ways that cannot be predicted
from first principles.
Methodology/Principal Findings: The optimization criterion in our experiments was the percent encapsulation of a target
drug, Amphotericin B, detected experimentally via spectrophotometric assay. Optimization of such a complex system
requires strategies that efficiently discover solutions in extremely large volumes of potential experimental space. We have
designed and implemented a new strategy of evolutionary design of experiments (Evo-DoE), that efficiently explores high-
dimensional spaces by coupling the power of computer and statistical modeling with experimentally measured responses
in an iterative loop.
Conclusions: We demonstrate how iterative looping of modeling and experimentation can quickly produce new discoveries
with significantly better experimental response, and how such looping can discover the chemical landscape underlying
complex chemical systems.
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Introduction
Formulation of a stable lipid membrane with good drug
complexation characteristics is a complex experimental problem
as there are many possible components (qualitative variables) with
a wide range of relative amounts (quantitative variables) in the
recipe. This makes drug formulation a good test case for
methodologies for discovering and optimizing complex chemical
systems. The experiments we present have five qualitative factors
and nine components whose concentrations are varied in the
aqueous phase, to form an experimental space that contains a total
of 82,950 possible experiments.
The experimental approach to the optimization problem
considered here is iterated high-throughput experimentation.
Many experiments are performed in parallel (e.g., using a 96-
well plate format), the results are analyzed, and a successive
generation of experiments is performed, with the goal of
progressively better results with each generation. After each
generation of experiments, the experimenter is faced with the
problem of designing a limited yet informative set of experiments
from an expansive experimental space for the successive
generation.
We address the problem of designing experiments for the
exploration of high-dimensional experimental spaces by applying
statistical modeling and predictive methods to the entire
experimental space at each generation. We build models from
the raw experimental data, and we use those models to choose
where next to sample the experimental space. This methodology is
iterated as illustrated in Figure 1. Our procedure is a form of
evolutionary design of experiments (Evo-DoE), building on
previous work based on genetic algorithms, where experiments
in each generation were specified by a genetic code, using genetic
operators (mutations and crossovers) to generate new experiments
for each successive generation [1–5]. The approach used here
differs primarily in that new experiments are chosen not only by
random variation, but also based on statistical modeling.
To start the optimization process, we sparsely sample the
experimental space with a random selection of experiments. We
build models of the desired response from the experimental data,
design the next sparse sampling of the experimental space, and the
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modeling and predictive algorithms enables successful optimiza-
tion of desired chemical behavior of supramolecular structures in
large high-dimensional experimental spaces.
The problem of designing each successive generation of
experiments is difficult for two related reasons: the statistical
uncertainty of any predictive model given the relatively small
amount of data (,10
2–10
3 samples), and the size of the space
(particularly when the number of dimensions (experimental
variables) is large). Large regions of the space are inevitably
unrepresented in the experimental data. To address the first
difficulty, we use a bootstrapping procedure in the model-building
process to ensure that the model’s complexity is not excessive given
the quantity of data available. The second difficulty is handled by
combining model-based prediction of experiments with a weighted
random sampling of the experimental space, where the distribu-
tion for the random sample is biased toward the unsampled
regions of the space. Given these two difficulties, our approach to
the experimental design problem may be seen as an example of
establishing an exploration/exploitation tradeoff [6], and is a high-
dimensional analogue of the technique known as Kriging in
geostatistics [7].
Traditional approaches to DoE for high-dimensional experi-
mental spaces use a ‘‘screening design’’ to identify a few significant
factors of many potential ones, or to identify a few significant
factors that embody the ‘‘main effects’’ that are presumed to be an
order of magnitude more important than ‘‘interaction effects’’ [8].
Screening designs are typically highly fractionated two-level (and,
very rarely, three-level) factorial designs. This approach fails for
complex systems because the interactions are typically not first
order, but second order. Systems that have several significant
qualitative factors with more than two levels, mixture systems
crossed with factorial systems, and other such complex designs
cannot be fractionated to implement a screening design.
Conventional DoE software does not include facilities to code
systems that are several sub-designs crossed with each other, like
the one described here, which is seen below to be approximately a
267 factorial crossed with a 2
2 factorial crossed with a 3-
component constrained mixture crossed with a constrained
multilevel qualitative factorial.
Amphotericin B is an antifungal drug used to treat systemic
fungal infections. The drug can cause nephrotoxicity if present in
high doses. However, when intercalated within a lipid membrane,
the hydrophobic drug can be administered to a patient with
minimal toxic effects. There are currently three different lipid
formulations of Amphotericin B on the market [9]. Each
formulation consists of different lipids associated with the drug
molecule, indicating that there is more than one way to effectively
package the drug into a lipid structure. Of these three, AmBisome
[10,11], has been the most effective and profitable.
In experiments presented here, we describe an Evo-DoE
procedure to search within a defined space of 82,950 possible
experiments for lipid combinations that maximize the amount of
Amphotericin B entrapped in the formulation. In a space of this
size and complexity, exhaustive screening is impractical, conven-
tional DoE has severe difficulties handling the multiple qualitative
variables, and simple hill-climbing approaches tend to fail because
of the interaction effects in the system. Within a few iterations
(exploration of ,0.5% of the space) we found many new
promising Amphotericin B formulations not previously reported.
In addition we were able to determine experimentally the response
surface for the lipid-drug combinations.
Results
Evo-DoE is an iterated, cyclical process involving experimen-
tally measuring responses of sparsely sampled recipes from a space
of possible experimental recipes. One approach to implementing
Figure 1. Illustration of the iterated high throughput experimental process. Note the predictive modeling procedure in the loop.
doi:10.1371/journal.pone.0008546.g001
Evo-DoE
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possible experiment a genetic code, and then progresses from one
generation of experiments to the next by applying genetic
operators analogous to mutation and crossover to winning recipes
[1–5]. Here, we explore the experimental space by modeling the
entire response surface on the basis of the collected experimental
data, and then use that model to choose the next set of recipes to
test experimentally. The models used here are feed-forward, single
hidden-layer artificial neural networks [12].
The Evo-DoE process used here started with a set of 90
randomly selected recipes that included all the pairwise combina-
tions of lipids in our lipid library. The N
th iteration of the Evo-
DoE process consisted of the following steps:
1) Measure the experimental response of the N
th set of recipes;
2) Optimize the metaparameters of the N
th model, as described
below;
3) Build a model of the entire response surface from the
experimentally measured responses for the first N sets of
recipes;
4) Randomly choose 48 recipes from the untried recipes with
the top quartile of responses predicted by the model, and
add those recipes to the N+1
th set of recipes;
5) Add 12 more randomly selected untried recipes to the N+1
th
set of recipes.
Neural network metaparameters are often optimized by a
‘‘bootstrapping’’ process [13]. At step 2 of the Evo-DoE cycle,
model metaparameters were dynamically optimized via the
following procedure: Models with different configurations of
metaparameters were trained on 20 different datasets, each one
a random sample of 70% of the experimentally observed
responses. The models were then tested on the remaining 30%
of the responses. The accuracy of a given model (correlation of
out-of-sample predictions with measured responses) was computed
as the accuracy averaged over the 20 different data sets. Finally,
the metaparameter configuration that gave the highest accuracy
was selected.
The response of each recipe was calculated as follows: Three
spectrophotometric absorbance measurements were taken from
experimental replicates in three separate wells of a 96-well plate at
three different times, and the response of a recipe was defined as
the average of those nine measurements.
The system was quickly optimized (Figure 2), after individually
testing 450 individual recipes from a space hundreds of times
larger. Even with a fairly substantial amount of noise, common in
real chemical systems, a clear optimum was reached as subsequent
generations thoroughly explored the same subregion without
resulting in further increased response. The amount of noise is
apparent from the spread of points for the standard: The control
recipe replicated each generation The optimum has a response
roughly twice that of the standard, indicating that the recipes have
more Amphotericin B in the lipid phase. The standard was
prepared using the AmBisome recipe [10,11], but with our
protocol.
More detailed analysis of the high response optimum found by
Evo-DoE is shown in Figure 3 as a set of 2-dimensional sections of
one 3-dimensional section of the entire space.It was generated
from a Microsoft Excel pivot table based on the three most
important factors found through our Evo-DoE: PG-type lipids,
negatively charged lipids, and aqueous factors (complete identifi-
cation of lipids and aqueous factors is given in the Materials and
Methods section). The numbers in each cell are average response
values, and the cells are color coded (with three color levels and
blank cells). From this representation it is clear that there are
substantial high response ridges for components DSPG, Bicine,
and DOPM, with lesser ridges for linoleic acid, PS, and oleic acid.
The abundance of every library component for each successive
generation of Evo-DoE was recorded. The results shown in
Figure 4 are for the PG lipid group and the negatively-charged
lipid group (other groups not shown). In Figure 4A the strong
selection for DSPG is apparent starting in the second generation
while the representation of other competing lipids fluctuates. In
Figure 4B, selection for DOPM, PS and linoleic acid is shown
during the exploration and optimization by our protocol.
We chose a sampling of winning recipes found by Evo-DoE
based on high response and diversity of components. We then
analyzed this group of twelve recipes for the formation of vesicles
and stability over time at varying temperatures, and normalized
each result based on the standard recipe. It should be noted that
we based our response function here solely upon the amount of
Amphotericin B associated with the lipids and not on these
secondary criteria. However, a response function could in
principle combine all three criteria.
The results of the analyses of the winning recipes are shown in
Table 1. Due to the selection criteria, it is not surprising that all
selected recipes show better Amphotericin B incorporation
(‘‘response’’) over the standard. For internal volume values that
indicate the presence of liposomes, all but one of the selected
recipes show lower volumes than the standard. This indicates the
presence of liposomes but suggests that they are not as voluminous
as liposomes prepared using the standard recipe. Surprisingly, the
stability tests indicate that all of the selected recipes are more stable
than the standard. We found the standard to be quite unstable and
a few of our new recipes to be stable after 30 days as evidenced by
the lack of aggregates in the formulations.
Discussion
The experimental space of this system was large and complex,
consisting of a 5-factor qualitative/mixture design in lipids crossed
with a 762 factor design in the aqueous phase. There were 82,950
possible combinations, far exceeding the throughput of the
experimental system. Traditional DoE methods handle such
complex systems with great difficulty. They were designed to
Figure 2. Rank order of all tested formulations found with Evo-
DoE vs. the standard recipe. Error bars on the best new recipe were
taken from three repeats performed on the same day (space repeats,
see Materials and Methods). The error bars from the standard were
taken from 75 total repeats performed over the course of the
experiment.
doi:10.1371/journal.pone.0008546.g002
Evo-DoE
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among the system components are weak enough that the space can
be simplified [14]. Most DoE software (e.g., Design-Expert, JMP)
is not even equipped to describe this kind of system properly.
Genetic algorithms have been used in iterated high throughput
optimization [1–5]. Their inherent stochastic nature makes them
less efficient than the predictive modeling-based system presented
here. Our predictive Evo-DoE algorithm is adapted for real
chemical systems and was able to code the experimental system
and rapidly reach an optimum.
It is important to note that the predictive model of the Evo-DoE
method presented here is a statistical model built entirely from the
available experimental data, and contains no expert prior
knowledge regarding reactions or self-assembly processes. Neither
does it contain structural information as in QSAR models [15].
Future work will consider addition of these informational
components into the modeling process.
This refined method of model-based screening resulted in rapid
and effective location of an optimum formulation of vesicle-
encapsulated Amphotericin B. The optimum was found using only
0.5% of the total possible points, and so may be only a local
optimum, but coverage of the space was nevertheless quite broad.
Many formulation variations are possible and available for
characterization and development into commercially viable
products.
It is also possible to get a rough picture of the response
landscape dictated by the lipid and aqueous phase combinations
and their interactions with the target. The high dimensionality and
qualitative nature of the factors makes conventional visualization
difficult. We found it best to section the measured response surface
to get intuitions about its topology, as shown in Figure 3.
The solutions found in our system may also be influenced by the
particular high throughput method we employed, as new recipes
were selected from previous ones based on how well the latter
Figure 3. Representation of a 3-dimensional section of experimental space. For each PG-type lipid, shown in bold, the horizontal section
lists the lipids from the group with a net negative charge and the vertical section lists the reagents in the aqueous phase and their corresponding pH
values. Response levels (the UV/Vis absorbance of Amphotericin B associated with the formulation): dark grey, .0.20; medium grey, 0.15–0.20; light
grey, 0.10–0.15; white, ,0.10; Blank cells, not determined. For abbreviations, see Materials and Methods.
doi:10.1371/journal.pone.0008546.g003
Evo-DoE
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protocols may place other selective factors or stresses on the
system and produce different optima. However, we found many
different types of recipes that can be used for Amphotericin B
formulation. Other groups using different protocols have also
found some of the factors that contributed to a positive response in
our system. For example, the specific favorable interaction
between Amphotericin B and the lipid DSPG has been known
for some time, and forms the basis for the Ambisome patent
(Figure 2; see [11]). However, we also found some interesting
synergies among the recipe components that have not been
previously described, such as the substitution of linoleic or oleic
acid for the phospholipid component (typically DOPC as in the
standard). Although successful formulations of Amphotericin B
have been developed since the 1980s [9], there may be many
different beneficial drug formulations that have yet to be
discovered, some perhaps possessing better stability and pharma-
cokinetics.
Although our response function did not include other important
parameters for drug formulation development, such as structure of
the resulting particles, stability of the formulation over time, or
pharmacokinetics, these could be included in a response function.
The predictive Evo-DoE framework can accommodate the
incorporation of such parameters. We have characterized the
structure and stability of the fittest drug formulations post-
optimization, and see variation in these parameters. Using our
protocol with a multi-component response function would allow
direct optimization of drug formulations, from the initial
incorporation of drug into lipid structures through to animal
models.
Our Evo-DoE methodology ‘‘closes the loop’’ in iterated
adaptive experimentation in a high-dimensional experimental
space. This closed loop can be fully automated if autonomously
operating robots are used to conduct high-throughput experimen-
tation, with the results fed directly into computers for automated
statistical analysis of experimental results, and then automated
intelligent design of the subsequent round of experiments could be
fed directly back into the experimental robot platform. This can
ultimately lead to 24/7 operation and rapid optimization of
Figure 4. Changeover timein lipid components in recipes tested.
Therepresentation of eachlipid, computed as a percentage of recipes that
have each particular component, for each generation of Evo-DoE is shown
for seven successive generations. For generation 2–7, only model-based
recipes are considered. A) The PG lipid group; B) the negatively charged
lipid group. See Materials and Methods for abbreviations and groupings.
doi:10.1371/journal.pone.0008546.g004
Table 1. Selected high-response formulations.
Recipe Lipid phase Aqueous phase Response Internal Volume
Stability
at 4uC
Stability
at 25uC
Stability
at 50uC
Std DSPG, Chol, DOPC Succinic Acid 10 mM, pH 4.5, Na(OH), Sucrose 9%. 1.0 1.00 1.0 1.0 1.0
1 PS, Chol, SM Bicine 100 mM, pH 8.5, Na(OH), Glucose 9%. 1.8 0.50 1.1 3.7 5.0
2 DSPG, Chol, DOPM Bicine 100 mM, pH 8.5, Na(OH), Sucrose 4.5%. 1.7 N.A. 1.11 3.7 4.3
3 DSPG, Ergo, Lino Mes 100 mM, pH 7, Na(OH), Sucrose 9%. 1.3 0.98 2.0 5.3 6.7
4 DSPG, Chol, DOPM Bicine 10 mM, pH 8.5, Na(OH), Sucrose 9%. 1.8 0.52 2.0 4.7 5.0
5 DSPG, Chol, DOPM Mes 10 mM, pH 7, Na(OH), Sucrose 4.5%. 1.7 N.A. 1.8 5.7 6.0
6 DSPG, Chol, Oleic Bicine 100 mM, pH 8.5, Na(OH), Glucose 4.5%. 2.0 0.40 2.2 6.7 6.7
7 DMPG, Chol, DOPM Bicine 100 mM, pH 8.5, Na(OH), Glucose 9%. 2.2 N.A. 2.0 3.0 4.7
8 DMPG, Chol, DOPM Bicine 100 mM, pH 8.5, Na(OH), Glucose 4.5%. 1.9 0.26 1.4 3.3 5.0
9 DPPC, Ergo, SM Bicine 10 mM, pH 8.5, Na(OH). 1.7 N.A. 2.1 6.7 5.0
10 PC, Chol, PS Bicine 100 mM, pH 8.5, Na(OH), Glucose 9%. 2.0 0.20 2.0 5.7 5.7
11 PC, Chol, Lino Bicine 100 mM, pH 8.5, Na(OH), Glucose 9%. 2.0 N.A. 2.1 5.7 6.7
12 DOPC, Chol, SM Bicine 100 mM, pH 8.5, Na(OH), Glucose 4.5%. 1.9 N.A. 1.0 3.3 4.3
doi:10.1371/journal.pone.0008546.t001
Evo-DoE
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milestone in automating the scientific process [16].
The task of discovering and optimizing complex chemical
systems suffers from two recurring problems: First, beneficial
nonlinear interactions among system components cannot be
inferred from basic chemical and physical laws, and second, as
the number of system constituents and experimental parameters
increases, traditional screening of experimental spaces becomes
impractical and economically unfeasible. The general method
applied here to optimize liposomal formulations of Amphotericin
B, predictive Evo-DoE, can be used generally to discover and
optimize other kinds of complex chemical systems, thus yielding a
new tool for solving the problem of chemical complexity.
Materials and Methods
Materials
Aqueous components. Water, mes, phosphate buffered saline
(PBS), glutamic acid (Glu), succinic acid (Succ), hepes, bicine and
trizma (Tris) were purchased from Sigma Aldrich. Sodium hy-
droxide was purchased from Merck.
Solvents. Chloroform, ethanol, methanol and dimethyl sulfox-
ide (DMSO) were purchased from Sigma Aldrich.
Lipids and amphiphiles. Egg PC (L-a-phosphatidylcholine,
hydrogenated), POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine),
DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), POPG (1-
palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)]) (sodium
salt), DPPG (1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)])
(sodium salt), DMPG (1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)]) (sodium salt), DSPG (1,2-distearoyl-sn-glycero-3-[phospho-
rac-(1-glycerol)]) (sodium salt) and DOPM (1,2-dioleoyl-sn-glycero-3-
phosphomethanol) (sodium salt), were purchased from Avanti Polar
Lipids. Cholesterol, ergosterol, sphingomyelin from bovine brain
$98%, (Sphingo) 1,2-diacyl-sn-glycero-3-phospho-L-serine solution
(PS), cardiolipin sodium salt from bovine heart (CL), oleic acid,
myristoleic acid (Myri) and linoleic acid (Lino) were purchased from
Sigma Aldrich.
Amphotericin B from Streptomyces ssp. in powder form and b-
octylglucopyranoside (BOG) in powder form was purchased from
Fluka. Sepharose 4B, Rhodamine 6G, calcein, glucose and sucrose
were purchased from Sigma.
Methods
Buffers preparation method. Buffers of stock solution,
100 mM, pH 4.5–7 and 8.5, NaOH were prepared and stored
at 4uC. Buffer titrations were performed with a solution of 10M
NaOH in water to adjust pH.
A library of 75 buffers was required to cover all possible
combinations of 7 different acids at 2 concentration levels, 3 pHs,
and 2 sugars at 2 concentration levels. All were stored at 4uC and
used at room temperature (23uC).
Detergent preparation method. The BOG detergent
powder was dissolved in water to a 20% (w/v) final concentration.
The solution was stored at 4uC.
Phospholipids preparation method. Stock solutions of
phospholipids in HCCl3, HCCl3/MeOH 3:1 or HCCl3/MeOH
95:5 were prepared and stored under nitrogen in Chromacol
screw cap vials with silicon/teflon septa (Microcolumn Srl), and
stored at 220uC. DOPC, POPC, DPPC, PC (egg), SM, PS,
DOPM, oleic acid, myristoleic acid, linoleic acid, cholesterol and
ergosterol were prepared at 5 mM and diluted when needed to
1 mM. CL, DPPG, POPG and DMPG were prepared at 6 mM
and diluted to 0.6 mM. DSPG in powder was prepared at
0.6 mM.
Amphotericin B preparation method. Amphotericin B
powder was dissolved in DMSO at 3.3 mM. A clear orange
solution was obtained and stored at 4uC.
Instrumentation
Absorbance measurements. Absorbance measurements at
415nm in the high-throughput experiment were recorded with a
PerkinElmer Wallace 1420 Victor 3 Multilabel Counter, designed
for 96-well plates. Absorbance spectra of the Amphotericin B in
aqueous solution and in solution with vesicles were recorded with
a PerkinElmer Lambda 25 spectrophotometer, using a quartz
cuvette.
Liquid handling. The high-throughput experiment was
performed with a robotic workstation for liquid handling, Xiril
75-1-2 (Switzerland). The hardware layout was designed
specifically for the experimental protocol developed. The library
of buffers, DMSO and BOG were contained in Chromacol 10 SV
tubes and placed in a removable stainless steel tube decktray for
the Xiril 75 with 96 12675 mm positions. The dilution steps of the
protocol were performed in 1.5 mL Eppendorf tubes, set in 32
position racks for 1.5 or 2 mL microfuge tubes with lids. At the
end of the experiments the racks containing the buffers, DMSO
and BOG were stored at 4uC. The custom racks were purchased
from Xiril. The robot workstation uses Rainin tips GPS-L250
space saver 960PZ purchased from Elettrofor Sas, Rovigo, Italy.
High-throughput protocol. The following section describes
the chemical high-throughput experiment protocol for preparing
and analyzing formulations containing Amphotericin B. The
DMSO solution containing Amphotericin B (crystallized at 4uC) is
warmed on a standard heatblock until it becomes liquid. 2.87 mlo f
the Amphotericin B solution are transferred by pipette into the
bottom of 500 ml volume glass vials (Chromacol 05-MTV-96) and
then set in a 96-position deep well vial holder (Chromacol 05-
MTP-96) from Microcolumn Srl.
The well plate containing the Amphotericin B vials is then
placed in the robotic workstation and the lipids in organic solvent
were added to the vials according to a well map, which specifies
the exact qualitative and quantitative composition of the resulting
mixture in each of the wells. At the end of the distribution step,
each vial contains a mixture of three lipids and Amphotericin B.
The resulting plate containing the vials of organic solvent, lipids
and Amphotericin B is then transferred into a vacuum chamber
connected with a vacuum pump (KNF LAB, Pressure min 1.0 bar)
with Teflon membranes. A heatblock at 100uC is set under the
well plate for 20 minutes before it is removed and the evaporation
process is allowed to continue for another 40 minutes, achieving a
thin yellow film on the glass surface of the vials. The well plate is
then transferred again to the robotic workstation and 200 ml of the
hydration aqueous phase are added according to a well map. The
final concentration of the lipids in the mixture is always 500 mM.
Once the lipid film is hydrated it is sonicated at 25uC for
10 minutes (Bandelin Sonorex Digitec), to promote the formation
of small unilamellar vesicles (SUV). The robot then transfers
140 ml of the sonicated vesicle solution into Eppendorf tubes,
prefilled with 240 ml of buffer. The samples are then centrifuged
(Heraeus Biofuge Pico) at 13610
3 rpm for 15 minutes to separate
the Amphotericin B entrapped in the formulation from free drug
crystals in solution. A yellow pellet representing the free drug
precipitate is visible on the bottom of the Eppendorf tubes.
178.5 ml of the supernatant is pipetted carefully into new 1.5 ml
Eppendorf tubes and repositioned in the robot. To each sample,
the robot adds 21 ml of DMSO and 10.5 ml of BOG, reaching a
Evo-DoE
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sample, leaving the Amphotericin B free in the organic solvent to
be analyzed spectroscopically.
The robot transfers 200 ml of the resulting solution into a
transparent 96-position micro-titration plate. The well plate is
covered and stored at 4uC overnight. Before measuring the
absorbance of the solution with the spectrophotometer, any bubbles
in the samples are removed with a gentle stream of nitrogen.
Triplicate absorbance measurements are made at 415 nm.
Stability tests. Formulations containing Amphotericin B
based on twelve selected top recipes and the standard were
prepared as above. The formulations were then split and
incubated in parallel at 4uC, 25uC, and 50uC, over the course of
30 days. For analysis, an aliquot of 10 ml was placed on a slide with
10 mM Rhodamine 6G and analyzed with fluorescent microscopy
(Nikon TE2000-S inverted fluorescence microscope with
Photometrics Cascade II 512 camera and in-house software).
The samples were visualized with a 406objective and 10 different
frames were captured per sample. The captured frames were then
analyzed for the presence of aggregates as evidenced by small dye-
containing lipid particles. They were scored as according to the
criteria: score of 0 for no aggregates seen, 1 for at least one
aggregate in only one captured frame, 2 for one aggregate in more
than one independent frame, 3 for at least one aggregate in all
frames, 4 for many aggregates in all frames. These scores were
then averaged over the time course of the experiment and
normalized to the standard.
Encapsulated volume estimation. Formulations containing
Amphotericin B based on selected top recipes and the standard
were prepared as above, but with 10uM calcein in the hydration
buffer. The unencapsulated external dye was then separated from
the lipid formulations using size exclusion chromatography
(sepharose 4B column, 661cm). The percent dye encapsulated
was then quantified on the PerkinElmer Wallace 1420 Victor 3
Multilabel Counter. The values were then normalized to the
standard.
Response function. Response values are calculated from
the absorbance of Amphotericin B after the removal of the
uncomplexed Amphotericin B crystals in solution and after the
destruction of the retained vesicle formulation with BOG as
detergent. The Amphotericin B absorbance spectrum shows several
peaks depending on the physical state of the Amphotericin B
[17,18]. Adding detergent in lipid solutions drives the micellization
process and destroys the vesicles [19], which according to their
large colloidal size absorb and scatter light over a broad spectrum,
with a critical micellar concentration of 0.025 M [20]. By
effectively cancelling out the effect of the liposomal structures
and any difference in absorbance due to specific Amphotericin B-
lipid interaction, absorbance peaks quantified here are determined
directly from the abundance of Amphotericin B. The quantification
of Amphotericin B was calculated from the absorbance of the
molecule using the linear region of the titration curve.
Experimental design (Evo-DoE). The full experimental
space of this experiment contained 82,950 possible recipes. It
consisted of all possible combinations of the following two libraries:
N An aqueous phase library (Table 2) consisting of all
combinations of a buffer (15 possibilities of seven buffers at
two levels, or water only) and a sugar (5 possibilities of two
sugars at two levels, or no sugar), for a total of 75 possibilities.
N A lipid library (Table 3) consisting of combinations of pairs of
four types of lipid (1–5 members each) with two sterols. The
library was constructed using six possible combinations: (1) PC,
PG, sterols (40 possibilities), (2) Negatively charged, PG, sterols
(40 possibilities), (3) Sphingo, PG, sterols (10 possibilities), (4)
PC, negatively charged, sterols (50 possibilities), (5) Sphingo,
negatively charged, sterols (10 possibilities), or (6) PC, Sphingo,
sterols (8 possibilities), for a total of 158 possibilities.
Because the lipid combinations form a mixture system, the
range of quantitative possibilities (relative concentrations of each
of the lipid types) is a polytope. The polytope and its extreme
vertices were generated using JMP software, and a set of the four
vertices, two midpoints, and the overall centroid were selected for
the experiments, for a total of seven concentration profiles for each
of the 158 lipid combinations.
Thus, the total number of possible combinations is given by 75
(buffers) * 158 (qualitative lipid mixtures) * 7 (quantitative lipid
possibilities)=82,950 (total experimental space).
Applying conventional DoE methods to a complex system like
this is very difficult. We attempted to generate a screening design
using two major software packages (JMP and Design-Expert) and
found them incapable of dealing with multilevel qualitative factors
with the sorts of constraints specified for the lipid library.
Experimentation using iterated high-throughput screening and
Evo-DoE begins with an initial generation selected from the whole
experimental space. In standard methods such as genetic algo-
rithms, this selection is random. More recently, low-discrepancy
random sequence protocols have been used to avoid the gaps and
overlapping points that frequently arise in the random approach, by
biasing the random sampling toward unsampled regions of the
experimental space. This is essentially a high-dimensional version of
the stochastic sampling used in Kriging [7]. We further refined the
initial generation using the concept of incomplete factorial
experiments, by using a balanced design as the first generation
[21,22]. Our results from the earlier experiments and simulations
have shown that two-way interactions appear to form the ‘‘ridges’’
our algorithm explores to find the peaks; this balanced design
Table 2. Aqueous phase library.
Buffers pH group Levels (mM) Sugars Levels (%)
HEPES 7 10, 100 Glucose 4.5, 9
MES 7 10, 100 Sucrose 4.5, 9
Glutamic acid 8.5 10, 100 No Sugar
Succinic acid 4.5 10, 100
Bicine 8.5 10, 100
Tris 8.5 10, 100
PBS 7 10, 100
No buffer
doi:10.1371/journal.pone.0008546.t002
Table 3. Lipid library.
Lipid Categories Lipids
PC DOPC, POPC, DPPC, PC (egg)
PG CL, DSPG, DPPG, POPG, DMPG
Sterol Cholesterol, Ergosterol
Negatively charged PS, DOPM, oleic acid, myristoleic acid, linoleic acid
Sphingo Sphingomyelin
doi:10.1371/journal.pone.0008546.t003
Evo-DoE
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8546samples those ridges effectively. The recipe set was generated by
successively eliminating duplicative runs from a moderately large
number of initial random recipes. In subsequent generations 80–
90% of the points were selected by predictive modeling, and the rest
by a stochastic sampling algorithm described above.
Predictions of experiments were obtained from a neural network
model (learned with back-propagation using nnet in the R language
afterstandardizingallinputsandnormalizingtheoutputtothe[0,1]
interval) with 28 inputs and one output (levels ‘‘No buffer’’ and ‘‘No
sugar’’ in the aqueous phase were regarded as two separate input
variables, each taking on either zero or one). Each neural network
was constructed with particular metaparameter values (weight
decay and number of hidden nodes). The model’s metaparameters
were selected using a bagging process, repeating the model learning
on a number of different data sets, each being a different random
sample of the observed experiments, and a number of times on each
data set. Each configuration of metaparameters was then assigned a
quality measure, calculated as the median correlation between
observations and predictions over all the repeats.
Acknowledgments
This work was conducted as part of the European Union integrated project
PACE (EU-IST-FP6-FET-002035). Norman Packard and Gianluca
Gazzola acknowledge helpful conversations with Irene Poli. The authors
also thank the European Center for Living Technology.
Author Contributions
Conceived and designed the experiments: FC GG MAB JNC NHP MMH.
Performed the experiments: FC CBM AB MMH. Analyzed the data: FC
GG MMH. Contributed reagents/materials/analysis tools: MMH. Wrote
the paper: FC GG MAB AB JNC NHP MMH.
References
1. Weber L, Wallbaum S, Broger C, Gubernator K (1995) Optimisation of the
biological activity of combinatorial compound libraries by a genetic algorithm.
Angewandte Chemie International Edition in English 34(20): 2280–2282.
2. Singh J, Ator MA, Jaeger EP, Allen MP, Whipple DA, et al. (1996) Application
of genetic algorithms to combinatorial synthesis: A computational approach to
lead compound identification and lead optimization. Journal of the American
Chemical Society 118: 1669–1676.
3. Wolf D, Baerns M (2002) Evolutionary strategy for the design and evaluation
of high throughput experiments. In: Cawse JN, ed. Experimental design for
combinatorial and high throughput materials development. HobokenNJ: Wiley
Interscience. pp 147–162.
4. Cawse JN (2007) Experimental design in high-throughput systems.
In: Narasim B, Mallapragada SK, Porter MD, eds. Combinatorial materials
science. HobokenNJ: Wiley Interscience. pp 21–50.
5. Theis M, Gazzola G, Forlin M, Poli I, Hanczyc MM, et al. (2006) Optimal
formulation of complex chemical systems with a genetic algorithm. ECCS06
online Proceedings (P193), Oxford. Available: http://sbs-xnet.sbs.ox.ac.uk/
complexity/complexity_PDFs/ECCS06/Conference_Proceedings/PDF/p193.
pdf. Accessed 2009 December 15.
6. Pucci de Varias D, Megiddo N (2005) Exploration-exploitation tradeoffs for
expert algorithms in reactive environments. In: Touretzky DS, ed. Advances in
neural information processing systems. CambridgeMA: MIT Press. pp 1–8.
7. Diggle PJ, Ribeiro PJ (2007) Model-based geostatistics. New York: Springer
Series in Statistics. 230 p.
8. NIST/SEMATECH e-Handbook of Statistical Methods, http://www.itl.nist.
gov/div898/handbook/, section 5.3.3.2.6. Accessed 2009 July.
9. Boswell GW, Buell D, Bekersky I (1998) AmBisome (liposomal Amphotericin B):
A comparative review. J Clin Pharmacol 38: 583–592.
10. Adler-Moore JP, Proffitt RT (2002) AmBisome: Liposomal formulation,
structure, mechanism of action and pre-clinical experience. J of Antimicr Chem
49, Suppl S1: 21–30.
11. Profitt RT, Alder-Moore J, Chiang S-M (2004) Amphotericin B liposome
preparation. US Patent 6770290.
12. Haykin S (1998) Neural networks: A comprehensive foundation. 2
nd edition.
New Jersey: Prentice Hall. 842 p.
13. Davison AC, Hinkley DV (1997) Bootstrap methods and their application.
Cambridge: Cambridge University Press. 592 p.
14. Cawse JN (2002) Experimental design for combinatorial and high-throughput
materials development. New York: Wiley-Interscience. 342 p.
15. Selassie CD (2003) History of quantitative structure-activity relationships. In:
Abraham JD, ed. Burger’s medicinal chemistry and drug discovery, sixth edition,
volume 1: Drug discovery John Wiley & Sons. pp 1–48.
16. King RD, Whelan KE, Jones FM, Reiser PGK, Bryant CH, et al. (2004)
Functional genomic hypothesis generation and experimentation by a robot
scientist. Nature 427: 247–252.
17. Fujii G, Chang J-E, Coley T, Steere B (1997) The formation of Amphotericin B
ion channel in lipid bilayers. Biochem 36: 4959–4968.
18. Gagos M, Koper R, Gruszecki WI (2001) Spectrophotometric analysis of
organisation of dipalmitoylphosphatidylcholine bilayers containing the polyene
antibiotic Amphotericin B. Bioch et Biophys Acta 1511: 90–98.
19. Keller M, Kerth A, Blume A (1997) Thermodynamics of interaction of octyl
glucoside with phosphatidylcholine vesicles: Partitioning and solubilization as
studied by high sensitivity titration calorimetry. Bioch et Biophys Acta 1326:
178–192.
20. He L.-Z, Garamus V, Niemeyer B, Helmholz H, Willumeit R (2000)
Determination of micelle structure of Octyl-b-glucoside in aqueous solution by
small angel neutron scattering. J Mol Liq (89). pp 239–249.
21. Carter CW Jr, Carter CW (1979) Protein crystallization using incomplete
factorial experiments. J Biol Chem 254(23): 12219–12223.
22. DeLucas LF, Bray TL, Nagy L, McCombs D, Chernov N, et al. (2003) Efficient
protein crystallization. J Struct Biol 142: 188–206.
Evo-DoE
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8546